PubMed · 2013 · 30 citations · 12 references
PharmacyPediatricsPharmacoeconomicsCost-effectiveness AnalysisPediatric NutritionPharmacoeconomic ModelingCost-effectiveness ComparisonCost-effectiveness ModelingPharmacoeconomic EvaluationProbioticsAcute Diarrhea ManagementCost-benefit EstimationDirect CostsDouble-blind TrialsHospital Stay DurationPlacebo-controlled Efficacy AssessmentProbiotic InterventionProbiotic Therapy For Diarrhea
We studied the cost-benefit of using probiotics (Lactobacillus acidophilus and Bifidobacterium bifidum) in the treatment of 106 children hospitalized with acute diarrhea using a double-blind randomized, placebo-controlled trial. The median length of hospital stay was significantly shorter in the probiotics group than in the controlled group (2 versus 3 days, p=0.049), but the median duration of diarrhea and direct medical costs were not significantly different (4 versus 5 days, p=0.068 and 4,418.75 versus 4,778.75 Thai Baht, p=0.342). Taking into consideration parental income loss, a non-significant lower expense was seen in the probiotics group (6,800.33 versus 7,970.92 Thai Baht, p=0.177). A greater cost-benefit with the probiotic treatment is probable, but was not statistically significant in this small study. In conclusion, the probiotics tested shortened the duration of hospitalization of children with diarrhea but the total expenses were not different.
12
Global, regional, and national causes of child mortality in 2008: a systematic analysis
Robert E. Black, Simon Cousens, Hope L. Johnson et al. · The Lancet · 2010 · 3.1K citations
Recommendations for Probiotic Use—2011 Update
Martin H. Floch, W. Allan Walker, Karen Madsen et al. · Journal of Clinical Gastroenterology · 2011 · 204 citations